SGLT2 inhibitor (Empagliflozin 25 MG)
17MMHIS083
Approved small_molecule active
Quick answer
SGLT2 inhibitor (Empagliflozin 25 MG) for Type2 Diabetes is a Approved program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hospital Authority, Hong Kong
- Indication
- Type2 Diabetes
- Phase
- Approved
- Modality
- small_molecule
- Status
- active